Abstract
Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients (n=114; 228 specimen) by GeneChip and quantitative real-time RT–PCR, identifies ETS-related gene (ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells. Combined quantitative expression analysis of ERG with two other genes commonly overexpressed in CaP, AMACR and DD3, revealed overexpression of at least one of these three genes in virtually all CaP specimen (54 of 55). Comprehensive evaluation of quantitative ERG1 expression with clinicopathological features also suggested that ERG1 expression level in prostate tumor cells relative to benign epithelial cells is indicator of disease-free survival after radical prostatectomy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baldus CD, Liyanarachchi S, Mrozek K, Auer H, Tanner SM, Guimond M, Ruppert AS, Mohamed N, Davuluri RV, Caligiuri MA, Bloomfield CD and de la Chapelle A . (2004). Proc. Natl. Acad. Sci. USA, 101, 3915–3920.
Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs WB . (1999). Cancer Res., 59, 5975–5979.
Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM . (2001). Nature, 412, 822–826.
Gavrilov D, Kenzior O, Evans M, Calaluce R and Folk WR . (2001). Eur. J. Cancer, 37, 1033–1040.
Gelmann EP . (2003). Crit. Rev. Oncol. Hematol., 46 (Suppl.), S11–S20.
Hart AH, Corrick CM, Tymms MJ, Hertzog PJ and Kola I . (1995). Oncogene, 10, 1423–1430.
Hsu T, Trojanowska M and Watson DK . (2004). J. Cell Biochem., 91, 896–903.
Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM and Staudt LM . (2004). Cancer Cell, 5, 191–199.
Isaacs W and Kainu T . (2001). Epidemiol. Rev., 23, 36–41.
Liu AY, Corey E, Vessella RL, Lange PH, True LD, Huang GM, Nelson PS and Hood L . (1997). Prostate, 30, 145–153.
Nelson WG, de Marzo AM and Isaacs WB . (2003). N. Engl. J. Med., 349, 366–381.
Oikawa T and Yamada T . (2003). Gene, 303, 11–34.
Owczarek CM, Portbury KJ, Hardy MP, O'Leary DA, Kudoh J, Shibuya K, Shimizu N, Kola I and Hertzog PJ . (2004). Gene, 324, 65–77.
Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S . (2004). Oncogene, 23, 605–611.
Reddy ES, Rao VN and Papas TS . (1987). Proc. Natl. Acad. Sci. USA, 84, 6131–6135.
Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D and Chinnaiyan AM . (2002). JAMA, 287, 1662–1670.
Sementchenko VI, Schweinfest CW, Papas TS and Watson DK . (1998). Oncogene, 17, 2883–2888.
Srikantan V and Srivastava S . (2003). Prostate Cancer. Hofmann R, Heidenreich A, Moul JW (eds) Springer-Verlag: Berlin, pp 25–40.
Acknowledgements
The prostate tissue specimens used in this study were obtained under an IRB-approved protocol at Walter Reed Army Medical Center. Informed consent was obtained from each subject. We thank DK Watson for providing ERG1 and ERG2 cDNA clones and for critically reading the manuscript. This work was funded by the CPDR through an ongoing grant from the US Army Medical Research and Materiel Command and by NIH Grant RO1 DK065977 to SS. None of the authors have competing financial interests. The opinions and assertions contained herein are the private views of the authors and are not to be construed as reflecting the official views of the US Army or the Department of Defense.
Author information
Authors and Affiliations
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Petrovics, G., Liu, A., Shaheduzzaman, S. et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847–3852 (2005). https://doi.org/10.1038/sj.onc.1208518
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208518
Keywords
This article is cited by
-
PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer
Scientific Reports (2022)
-
Race and prostate cancer: genomic landscape
Nature Reviews Urology (2022)
-
Identification of transcription factor co-regulators that drive prostate cancer progression
Scientific Reports (2020)
-
ERG oncoprotein expression in prostatic acinar adenocarcinoma; clinicopathologic significance
BMC Research Notes (2019)
-
Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies
Nature Reviews Urology (2019)